(E)-3-(4-tert-butoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)acrylamide

ID: ALA3898170

Chembl Id: CHEMBL3898170

PubChem CID: 73052223

Max Phase: Preclinical

Molecular Formula: C13H16N4O2

Molecular Weight: 260.30

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CC(C)(C)Oc1ncnc2[nH]cc(/C=C/C(N)=O)c12

Standard InChI:  InChI=1S/C13H16N4O2/c1-13(2,3)19-12-10-8(4-5-9(14)18)6-15-11(10)16-7-17-12/h4-7H,1-3H3,(H2,14,18)(H,15,16,17)/b5-4+

Standard InChI Key:  OIZYRHLPFJOIQM-SNAWJCMRSA-N

Alternative Forms

1. Parent:

   

   ALA3898170

   (E)-3-[4-[(2-methylpropan-2-yl)oxy]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]prop-2-enamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 260.30

Molecular Weight (Monoisotopic): 260.1273

AlogP: 1.63

#Rotatable Bonds: 3

Polar Surface Area: 93.89

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.68

CX Basic pKa: 4.97

CX LogP: 1.36

CX LogD: 1.36

Aromatic Rings: 2

Heavy Atoms: 19

QED Weighted: 0.82

Np Likeness Score: -0.36

References

1.  (2014)  4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment, 

2.  (2016)  4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment, 

Source

Source(2):

• BindingDB Database
• Patent Bioactivity Data